Spots Global Cancer Trial Database for mln0128
Every month we try and update this database with for mln0128 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | NCT02812056 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Alisertib TAK-228 | 18 Years - | M.D. Anderson Cancer Center | |
| Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | NCT02091531 | Metastatic Cast... | MLN0128 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | NCT02049957 | Breast Cancer | Sapanisertib Fulvestrant Exemestane | 18 Years - | Calithera Biosciences, Inc | |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Phase II Study of TAK228 in Relapsed Lymphoma | NCT02727777 | Lymphoma | TAK228 Blood Sugar Tes... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | NCT02724020 | Clear-cell Meta... | Everolimus MLN0128 MLN1117 | 18 Years - | Takeda | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | NCT03205891 | Malignant Neopl... Classical Hodgk... Anaplastic Larg... CD30+ Periphera... | Brentuximab Ved... TAK228 Glucose Monitor | 18 Years - | M.D. Anderson Cancer Center | |
| Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | NCT02987959 | Soft-tissue Sar... | TAK-228 | 18 Years - | Fox Chase Cancer Center | |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | NCT02724020 | Clear-cell Meta... | Everolimus MLN0128 MLN1117 | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
